Centi-B9 / Centivax - LARVOL DELTA

Centivax and U.S. Naval Medical Research Center Announce Strategic Partnership to Initiate Clinical Development of a Broad-Spectrum Injectable For COVID-19, With $4.2M From the Henry Jackson Foundation (PRNewswire) - "Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9...Centivax and NMRC will each contribute a Principal Investigator to the clinical study, and NMRC will host the Phase I clinical trial site for intramuscular and subcutaneous delivery of Centi-B9...The Henry Jackson Foundation is providing $4.2M US in non-dilutive funding support for the trial. The Phase I trial will demonstrate safety and pharmacokinetics of the Centivax monoclonal in healthy volunteers and is planned to begin in July of this year. These Phase I studies will enable a Phase II/III adaptive trial to begin later this year....Centivax will seek Emergency Use Authorization during interim analysis."

Licensing / partnership • New P1 trial • Infectious Disease • Novel Coronavirus Disease